Reconstruction using a vertical “sagging cheek” advancement flap for defects following full-thickness excision of non-melanoma skin cancer in the elderly: a case series

Non-melanoma skin cancer (NMSC) has become a major health concern, particularly with the growing aging population in society. The number of surgically treated squamous cell carcinomas (SCC) is comparable to that of basal cell carcinomas (BCCs) [1]. The preauricular area is a common primary site for SCCs in close association with chronic ultraviolet damage [2]. Although primary closure is a better solution in almost all circumstances, relatively large facial defects often pose a problem, especially [...

Computed tomography imaging findings in erythrodermic psoriasis treated with infliximab: A case report

Erythrodermic psoriasis (EP), 1 of the most rare and severe forms of psoriasis, is characterized by general erythema with silvery scales. Systemic vasodilatation in EP is potentially life-threatening, however, the degree and extent of inflammation in subcutaneous tissues are difficult to estimate accurately using standard skin inspections or ultrasound examinations. Computed tomography can be a useful modality in solving this problem. The authors report a case of EP. Sequential contrast-enhanced whole-body computed tomography before and after treatment with a tumor necrosis factor-α inhibitor (infliximab) visualized the inflammation and the effect of the treatment. Keywords: Erythrodermic psoriasis, Inflammation, Vasodilatation, Computed tomograph

Possible activation of effector B cells during drug‐induced hypersensitivity syndrome

Abstract Although the development of autoimmune disorders is recognized in drug‐induced hypersensitivity syndrome (DIHS), the serial change of B‐cell activity has not been well‐addressed. Herein, the serum levels of IL‐6, IL‐10, B‐cell activating factor of the tumor necrosis factor family (BAFF), and a proliferation‐inducing ligand (APRIL) in three DIHS patients were tracked over time. While IL‐6 and IL‐10 tended to be elevated according to the disease activity, BAFF and APRIL increased during the improved phase. Our results imply that the continuous activation of B cells may be involved in the prolonged disease activity of DIHS and the development of autoimmune disorders

Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF

BACKGROUND: Many patients with atrial fibrillation have concomitant coronary artery disease with or without acute coronary syndromes and are in need of additional antithrombotic therapy. There are few data on the long-term clinical outcome of atrial fibrillation patients with a history of acute coronary syndrome. This is a 2-year study of atrial fibrillation patients with or without a history of acute coronary syndromes